Genelux (GNLX) Income towards Parent Company (2022 - 2026)
Genelux (GNLX) posted quarterly Income towards Parent Company of -$9.3 million for Q1 2026, down 21.02% year-over-year from -$11.8 million in Q1 2025, and up 38.38% quarter-over-quarter from -$15.1 million in Q4 2025.
Genelux (GNLX) Income towards Parent Company (2022 - 2026) Analysis & Trends
Genelux's Income towards Parent Company history runs 5 years deep, the most recent figure standing at -$9.3 million for Q1 2026.
- In Q1 2026, Income towards Parent Company fell 21.02% year-over-year to -$9.3 million; the TTM figure through Mar 2026 stood at -$43.8 million (down 42.33% YoY), while the FY2025 annual figure was -$111.0 million, down 21.05% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$9.3 million, up from -$15.1 million in the prior quarter.
- The five-year high for Income towards Parent Company was $4.9 million in Q3 2022, with the low at -$117.2 million in Q2 2023.
- The 5-year median for Income towards Parent Company is -$8.1 million (2025), against an average of -$14.8 million.
- The sharpest annual moves came in 2023 and 2024: Income towards Parent Company tumbled 208.88% in 2023, then surged 94.26% in 2024.
- Genelux's Income towards Parent Company stood at -$3.5 million in 2022, then slumped by 93.62% to -$6.8 million in 2023, then plunged by 39.78% to -$9.5 million in 2024, then sank by 60.13% to -$15.1 million in 2025, then soared by 38.38% to -$9.3 million in 2026.
- Business Quant data shows GNLX's Income towards Parent Company at -$9.3 million in Q1 2026, -$15.1 million in Q4 2025, and -$11.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Genelux | 120.53 Mn | 120.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.33 Mn |
| Dec 31, 2025 | -15.15 Mn |
| Sep 30, 2025 | -11.28 Mn |
| Jun 30, 2025 | -8.06 Mn |
| Mar 31, 2025 | -7.71 Mn |
| Dec 31, 2024 | -9.46 Mn |
| Sep 30, 2024 | -6.89 Mn |
| Jun 30, 2024 | -6.73 Mn |
| Mar 31, 2024 | -9.50 Mn |
| Dec 31, 2023 | -6.77 Mn |
| Sep 30, 2023 | -5.35 Mn |
| Jun 30, 2023 | -117.16 Mn |
| Mar 31, 2023 | -9.57 Mn |
| Dec 31, 2022 | -3.50 Mn |
| Sep 30, 2022 | 4.91 Mn |